Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889465 | 0.88 | PLD2 (0.47) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5897347 | 0.85 | ITGB3 (0.54) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5896912 | 0.84 | NHERF1 (0.51) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5889682 | 0.83 | PLD2 (0.45) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5680470 | 0.80 | NHERF1 (0.48) | ITGB3ITGA2BMAOAMAOBNHERF1 | |
| SCHEMBL5896610 | 0.79 | ITGB3 (0.40) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5675941 | 0.79 | ITGB3 (0.44) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5889580 | 0.76 | PLD2 (0.43) | HRASESR1ESR2HDAC2ITGB3 | |
| SCHEMBL5677297 | 0.76 | ITGB3 (0.64) | HDAC2ITGB3ITGA2B | |
| SCHEMBL5889559 | 0.76 | HRAS (0.50) | HRASESR1ESR2HDAC2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | claimed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | HRAS 1309/4885ESR1 3790/4885ESR2 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.